

Oncology Summary

Patient: Maya Hernandez

MRN: ONC-2026-0142

Birth Date: 1978-09-12

Gender: female

Encounter Date: 2026-02-18

Oncologist: Dr. Priya Shah

Center: North Valley Cancer Center

Diagnosis: Metastatic breast carcinoma

Clinical Status: active

Stage: Stage IV

Body Site: left breast with liver metastases

Diagnostic Report

Report Type: Pathology and biomarker summary

Effective Date: 2026-02-12

Conclusion: Metastatic adenocarcinoma consistent with breast primary; ER positive, HER2-low, PD-L1 CPS 12.

Recent Observations

Hemoglobin: 11.2 g/dL on 2026-02-18

Absolute neutrophil count: $2.4 \times 10^9/L$ on 2026-02-18

Creatinine: 0.9 mg/dL on 2026-02-18

CA 15-3: 48.0 U/mL on 2026-02-18

Medications

Name: Capecitabine

Status: active

Dose: 1500 mg orally twice daily on days 1-14 of a 21-day cycle

Route: oral

Name: Ondansetron

Status: active

Dose: 8 mg every 8 hours as needed for nausea

Route: oral

Name: Zoledronic acid

Status: active

Dose: 4 mg every 28 days

Route: intravenous

Care Plan

Status: active

Intent: plan

Description: Continue capecitabine, repeat CT chest/abdomen/pelvis in 8 weeks, and return to clinic on 2026-03-11.